All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Efficacy and Safety of Rezum System Water Vapor Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00084914" target="_blank" >RIV/00216224:14110/15:00084914 - isvavai.cz</a>

  • Alternative codes found

    RIV/65269705:_____/15:00063563

  • Result on the web

    <a href="http://dx.doi.org/10.1016/j.urology.2015.05.046" target="_blank" >http://dx.doi.org/10.1016/j.urology.2015.05.046</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.urology.2015.05.046" target="_blank" >10.1016/j.urology.2015.05.046</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Efficacy and Safety of Rezum System Water Vapor Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

  • Original language description

    To assess 1-year efficacy and safety data from pilot trials of the Rezum System water vapor to treat lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). A total of 65 men with symptoms of moderate to severe BPH were enrolled in pilot studies at centers in the Dominican Republic, the Czech Republic, and Sweden. Each patient was treated with transurethral delivery of sterile water vapor (steam). International Prostate Symptom Score (1PSS), peak urinary flow (Qmax), qualityof life (QoL), postvoid residual, International Index of Erectile Function, and prostate-specific antigen were evaluated at 1 week and 1, 3, 6, and 12 months post-treatment. Safety was also assessed. Statistically significant clinical improvements at 1,3, 6, and 12 months were reported for IPSS (decreased by 6.8, 13.4, 13.1, and 12.5 points, respectively) and Qmax (increased by 2.0, 4.7, 4-3, and 4-6 mL/sec, respectively). At 12 months, these results equated to a 56% improvement in IPSS

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FP - Other medical fields

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2015

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Urology

  • ISSN

    0090-4295

  • e-ISSN

  • Volume of the periodical

    86

  • Issue of the periodical within the volume

    5

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    6

  • Pages from-to

    1042-1047

  • UT code for WoS article

    000366466400049

  • EID of the result in the Scopus database